Brand names like Ozempic, Wegovy, Mounjaro, and Zepbound from the likes of Eli Lilly and Novo Nordisk are commonplace, but the GLP-1 technology behind them is less well-known.

Weight loss therapies, or
GLP-1s, stimulate receptors to promote insulin synthesis, which helps regulate metabolism and blood glucose levels, and reduce appetite.

THNR-Weight-Loss-ETF-Scale
THNR-Weight-Loss-ETF-RX
THNR-Weight-Loss-ETF-Injection

$130 Billion1

Projected Market Size of GLP-1 therapies in 2030

10-20% Body Weight Reduction4

Treatment Breakthrough

42% of U.S. adults and 1 billion people worldwide are clinically obese2,3

Demand is Growing

Used to treat diabetes for more than 10 years4

Diabetes Treatment

Diverse Application Potential

202405_THNR Scale Icon_Reverse

Weight Loss

202405_THNR Heart Icon_Reverse

Reduced Cardiovascular and Stroke Risk

202405_THNR Brain Icon_Reverse

Impulsive Behavior Reduction

202405_THNR Rx MP Icon_Reverse

Sleep Apnea Treatment

202405_THNR Injection Icon_Reverse

Diabetes Management and Prevention

202405_THNR Microscope Icon_Reverse

Preventative Health Care

Explore our Weight Loss ETF:

Ticker_THNR_Dark
Amplify Weight Loss Drug & Treatment ETF
View THNR Prospectus →
Global Icon

Access a global equity portfolio of companies pioneering GLP-1 therapies and the broader supply chain to capitalize on demand.

Active Management Icon

Significant growth opportunity as the GLP-1 market is anticipated to grow from $6 billion to $130 billion by 2030.1,5

Transparency Icon

Due to increasing demand pharmaceutical companies are accelerating production of GLP-1 therapies.

Insights

ON DEMAND WEBCAST

Gain key insights into the significant growth opportunity in weight loss therapies featuring Christian Magoon, Founder & CEO of Amplify ETFs and Jane Edmondson, Head of Thematic Strategy at VettaFi.


Weight Loss, Investors Gain: The Investment Opportunity Presented by Weight Loss Treatment Innovations


Advisors:
Download our White Paper: Investment Case for GLP-1

Carefully consider the Fund’s investment objectives, risks, charges, and expenses before investing. This and other information can be found in the Fund’s statutory and
summary prospectuses, which may be obtained at AmplifyETFs.com. Read the prospectus carefully before investing.

Investing involves risk, including the possible loss of principal. There can be no assurance that the Fund’s investment objectives will be achieved. The fund is new with limited operating history. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. The Fund invests in securities included in its Index regardless of their investment merit and may experience tracking error: the differences in timing of trades, valuation, plus fees and expenses between fund and index.

A non-diversified fund can invest a greater portion of its assets in securities of individual issuers which could cause greater fluctuations than a diversified fund. A narrowly focused portfolio concentrated in the pharmaceutical industry or healthcare sector, may exhibit higher volatility and be vulnerable to factors affecting them due to regulation, litigation, costs and competition.

Small and/or mid-capitalization companies may be more vulnerable to adverse general market or economic developments. Investments in foreign securities, especially in emerging markets, involve greater volatility and political, economic, and currency risks and differences in accounting methods beyond those of securities of U.S. issuers.

Amplify Investments LLC serves as the investment adviser to the Fund. Penserra Capital Management LLC serves as the investment sub advisor to the fund. Amplify ETFs are distributed by Foreside Fund Services, LLC.

As of 06/05/2024 Eli Lilly is a 15.71% holding, and Novo Nordisk is a 14.98% holding in THNR.

1 https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
2 42% of U.S. adults are obese, source: https://www.pewresearch.org/short-reads/2024/03/21/as-obesity-rates-rise-in-the-us-and-worldwide-new-weight-loss-drugs-surge-in-popularity/
3 https://www.who.int/news/item/01-03-2024-one-in-eight-people-are-now-living-with-obesity
4 https://www.morganstanley.com/im/en-us/individual-investor/insights/articles/glp1-the-weight-of-speculation.html
5 https://www.goldmansachs.com/intelligence/pages/anti-obesity-drug-market.html